Checking Blood Sugar Tests for Diabetes in Adults Over 65
Studies A1c tests and glucose monitors in adults over 65.
Plain-language title generated from the registry record
Registry title: Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- Brigham and Women's HospitalBoston, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Brigham and Women's Hospital
- Trial code
- NCT07111416
- Record updated
- 29 October 2026
- Original description
The goal of this observational study is to learn why some adults over the age of 65, have A1c tests that do not match up with their blood glucose levels, also known as 'A1c-glucose discordance'.Read full original descriptionShow less
Personalizing A1c Using Hematologic Indices and CGM for Accurate Diabetes Diagnosis (PRECISE DM Dx)
The goal of this observational study is to learn why some adults over the age of 65, have A1c tests that do not match up with their blood glucose levels, also known as 'A1c-glucose discordance'.
The main question it aims to answer is:
Could alternative tests like CGM or personalized A1c provide more accurate diabetes screening in this population?
Participants will be asked to perform blood tests every week to two weeks and wear a CGM for up to 8 weeks.
Inclusion: Age 65 years of age or older; A1c 5.3% - 7.4% without a diagnosis on the problem list and/or current or prior treatment for diabetes; Evidence of A1c discordance by meeting one of two criteria developed by an EHR based algorithm; At least five (5) HbA1c values and three (3) CBC values available in the EHR in the previous 10 years; Willingness to wear an Abbott Freestyle Libre 3 System Sensor for up to 48 days; Willingness to consent to data collection using the electronic health record and sign a medical release to obtain future medical records from other health care facilities.
Exclusion: Active treatment for cancer, planned treatment for cancer, or recent active cancer with a likelihood of recurrence or progression, that, in the opinion of the site investigator, would interfere with study therapy prior to 2029; Allowed Exceptions: Treated cancer with no evidence of disease, no evidence of disease progression, and no planned change in therapy. Examples of allowable cancers include:; Breast cancer stable after active treatment, managed with long-term anti-estrogen therapy; Prostate cancer being observed; Stage 0 or 1 tumors status post resection or other definitive treatment; Other similarly stable cancer comorbidities; Known or suspected diabetes of other causes (type 1 diabetes, pancreatogenic diabetes, monogenic diabetes, etc.); Condition with short life expectancy; Blood (hematologic) malignancy; Unstable psychiatric or medical condition; Clinically significant anemia based on most recent hematocrit (M = <38%, F <33%) and/or hemoglobin (M = <12 g/dL, F = <10 g/dL) within the last 12 months; rtCGM-interference agents per manufacturer (e.g., high dose vitamin C).